COVID-19 Drug Shortages: EU Explores Tweaking National Forecasting Models
As COVID-19-related drug shortages continue to persist in the EU, regulators explore the possibility of drawing lessons from existing models that member states use to estimate national demand for medicines.
You may also be interested in...
A new system for monitoring the availability of medicines for treating COVID-19 patients will allow EU-level coordinated actions to address supply shortages in the best way.
The European Medicines Agency wants to make it clearer for drug sponsors what more they can do to address the presence of cancer-causing impurities in active substances, and how to deal with the issue in their regulatory submissions.
A surge in scientific advice requests in the latter half of 2021 forced the European Medicines Agency to delay the start of some procedures, but the situation has improved considerably since then.